Absynth Biologics aims to discover and develop vaccines to prevent and treat common bacterial infections. With antibiotic resistance on the rise, the development of vaccines to prevent drug-resistant infections, such as staph, could have huge implications for hospital budgets and patients alike.
With five patent families already filed support the two initial vaccines under development, Absynth Biologics is looking to take the next step in its growth.
If successful, Absynth’s programme will play an important part in combatting the problem of antibiotic resistance.
Investment Manager with Alderley Park Ventures, Absynth lead investor